Efficacy of letrozole as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer in Korea

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this study was conducted to affirm the efficacy and toxicities of letrozole in Korean patients. Materials and Methods This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medical records. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity. Results The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated. Conclusion Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

Original languageEnglish
Pages (from-to)454-463
Number of pages10
JournalCancer Research and Treatment
Volume49
Issue number2
DOIs
StatePublished - 1 Apr 2017

Fingerprint

letrozole
Korea
Hormones
Breast Neoplasms
Disease-Free Survival
Confidence Intervals
Therapeutics
Survival

Keywords

  • First-line treatment
  • Hormone receptor-positive
  • Korea
  • Letrozole
  • Metastatic breast cancer

Cite this

@article{77f63af509894b3eb61e90457179f230,
title = "Efficacy of letrozole as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer in Korea",
abstract = "Purpose Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this study was conducted to affirm the efficacy and toxicities of letrozole in Korean patients. Materials and Methods This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medical records. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity. Results The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95{\%} confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95{\%} CI, 38.1 to 74.7). The ORR was 36.9{\%} for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95{\%} CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤2 years (hazard ratio, 2.697; 95{\%} CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated. Conclusion Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.",
keywords = "First-line treatment, Hormone receptor-positive, Korea, Letrozole, Metastatic breast cancer",
author = "Beom, {Seung Hoon} and Jisu Oh and Tae-Yong Kim and Kyung-Hun Lee and Yaewon Yang and Suh, {Koung Jin} and Moon, {Hyeong Gon} and Sae-Won Han and Do-Youn Oh and Wonshik Han and Taeyou Kim and Dongyoung Noh and Seock-Ah Im",
year = "2017",
month = "4",
day = "1",
doi = "10.4143/crt.2016.259",
language = "English",
volume = "49",
pages = "454--463",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "2",

}

TY - JOUR

T1 - Efficacy of letrozole as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer in Korea

AU - Beom, Seung Hoon

AU - Oh, Jisu

AU - Kim, Tae-Yong

AU - Lee, Kyung-Hun

AU - Yang, Yaewon

AU - Suh, Koung Jin

AU - Moon, Hyeong Gon

AU - Han, Sae-Won

AU - Oh, Do-Youn

AU - Han, Wonshik

AU - Kim, Taeyou

AU - Noh, Dongyoung

AU - Im, Seock-Ah

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this study was conducted to affirm the efficacy and toxicities of letrozole in Korean patients. Materials and Methods This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medical records. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity. Results The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated. Conclusion Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

AB - Purpose Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this study was conducted to affirm the efficacy and toxicities of letrozole in Korean patients. Materials and Methods This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medical records. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity. Results The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated. Conclusion Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

KW - First-line treatment

KW - Hormone receptor-positive

KW - Korea

KW - Letrozole

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85017361054&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.259

DO - 10.4143/crt.2016.259

M3 - Article

C2 - 27554482

AN - SCOPUS:85017361054

VL - 49

SP - 454

EP - 463

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -